IPO-bound Veeda Clinical Research on Thursday announced that it has raised USD 16 million (around Rs 118 crore) in a funding round led by private equity fund Sabre Partners.
Without revealing the stake sold, the clinical research organisation backed by CX Partners termed this as a growth capital.
The round also saw participation from high net individuals like Pranab Mody of JB Chemicals, Havells India family office, Nikhil Vora of Sixth Sense Ventures, and Arjun Bhartia of Jubilant, as per an official statement.
The CRO industry is witnessing rapid growth resulting from a confluence of economic and regulatory tailwinds. We believe Veeda is well-positioned to capitalise on this opportunity as one of the largest independent full-service clinical research organisations, Sabre's founder and managing partner Rajiv Maliwal said.
The Ahmedabad-headquartered Sabre has invested USD 280 million in its nearly two-decade existence and returned USD 1.7 billion to investors from its three funds. The investment in Veeda is being done from its fourth fund which was launched in 2019.
Veeda's managing director Ajay Tandon said it aims to be the preferred research partner offering a broad range of drug development, pre-clinical, and clinical research services to global innovator, generic, and biopharma clients.
We will continue to invest in developing our delivery capabilities, to be increasingly relevant to our client's objectives, he added.
Veeda Clinical Research is proposing an initial public offering of its equity shares in the near future subject to receipt of requisite approvals, market conditions, and other considerations, and is in the process of filing a draft red herring prospectus with the Securities and Exchange Board of India, the statement said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU